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factor alpha (TN-F-) . granulocyte colony-stimulating factor (G-CSF) (Colombo et al.. 1991) and granulocyte-macrophage (GM)-CSF (Columbec et al.. 1993) .
Although the chemokines IP-10 (interferon-inducible protein 10) (Luster et al.. 1985) and MCP-1 (MCAF. JE) (monoc-te chemotactic protein 1) have recently been reported to has-e potent anti-tumour activitv in vivo (Bottazi et al.. 1 992: Rollins and Sundav. 1992: Luster and Leder. 1993) . the other chemokine famils members has-e not. thus far. been reported to have antitumour effects.
The chemokines are a superfamily of small proteins (M.U 8000-14 000) secreted primarilv by leucocvtes and related by a conserved four-cvsteine motif. The superfamily s two branches are classified as the C-X-C and C-C groups. as defined by spacing of the first txs-o cysteins in the conserved motif (Oppenheim et al.. 1991) . Generallv. C-X-C chemokines. such as IL-8 (the neutrophil attractant and activating factor) (Oppenheim et al.. 1991) . GRO MGSA (melanoma growthstimulatorx factor) (Anisowicz et al.. 1987) . IP-10 (Luster et al.. 1985) . and MIP-2 (macrophage inflammatory protein-2) . are potent chemoattractants and activators for neutrophils (Oppenheim et al.. 1991) . whereas the C-C chemokines. including such molecules as MCP-1 . . and RANTES (rezulated on activation. normal T expressed and secreted) (Schall et al.. 1990) (Oppenheim et al.. 1991) . The accumulation and activation of leucocvtes at sites of inflammation is induced by locally produced and secreted chemokines.
Since the chemokines has-e been reported to attract and stimulate immune cells. we has-e. therefore. evaluated the tumorngenicity and host anti-tumour response in mice given injections of CHO cells genetically modified to secrete chemokines. We has-e used nude mice to circumvent allogeneic reactions to the transfected cells and immunoresponse to chemokines.
Materials and methods
Expression plasmids Approximately 1.7 kb of hu-IL-8 cDNA and 0.33 kb of hu-MCP-1 cDNA A-ere isolated from a cDNA librarx of lipopolysaccharide (LPS)-stimulated human peripheral blood mononuclear cells (PBMCs) and a phorbol l2-mvristate 13-acetate (PMA)-pretreated monocvtic cell hne (THP-1) respectivelv (Matsushima et al.. 1988 : Furutani et al.. 1989 . and ligated into the BamHI HindIII-digested mammalian expression vector pHpApr-3p-neo (Gunning et al.. 1987) . The other chemokine cDNAs were isolated by poly-merase chain reaction (PCR) using reverse transcribed total RNA of PMA plus phytohaemagglutinin (PHA)-activated human PBMCs for hu-MIP-Ix (LD78) and LPS-stimulated mouse splenic cells for mu-MIP-lx. mu-MIP-2 and mu-MCP-1 according to published protocols (Lipson and Baserga. 1989) . The following primers were used: for hu-MIP-lcx (Obuku et al.. 1986 ): 5'-GTGAAGCTTCAGACAGTGGTCAGTCCTTTC-3' and 5'-CACGGATCCCCCTCAGGCACTCAGCTCTA-3': for mu-MCP-1 (Kawahara and Deuel. 1989) : 5'-GTGAAGCTTAG-CTCTCTCTTCCTCCACCACCA-3' and 5'-CACGGATC-CTTTACGGGTCAACTTCACATTCAAA-3': for mu-MIPlx (Wolpe et al.. One million CHO transfectants in 1 ml of culture medium were incubated in a 24-well culture plate at 37°C for 24 h. The amount of hu-IL-8 and hu-MCP-1 in culture supernatant was measured by RIA using a rabbit polyclonal antihu-IL-8 or -hu-MCP-l antibody developed in our laboratory (Endo et al., 1991) . Both recombinant (r) IL-8 and rMCP-l were labelled with '"I by the Bolton-Hunter method as previously described (Matsushima rich fractions were collected and contaminating erythrocytes were lysed with lysing solution (Ortho, Raritan, NJ, USA) by incubation for 5 min at 25'C. The purity of PMNs was >98% with more than 95% neutrophils. The chemotactic activity of hu-, and mu-MCP-l was assayed using human PBMC from healthy volunteers by Ficoll-Hypaque centrifugation.
Chemotaxis assay Neutrophil or monocyte chemotaxis assays were performed using multimicro-well Boyden chamber (Neuroprobe, Cabin John, MD, USA) as previously described (Falk et al., 1980) . A 25 1il aliquot of either supernatant (10-7 M N-formylmethionyl-leucyl-phenylalanine) (FMLP) (Sigma), (1-100 ng ml-), hu-rMCP-1 (1-100 ng ml-l) or phosphatebuffered saline (PBS) Animal studies Seven-week-old male BALB/c nulnu mice were purchased from Nihon Crea (Atsugi, Japan). Transplantation assays for each chemokine transfectant were performed successively in combination with CHO/neo as a control. Tumour cell injections were carried out using freshly prepared suspensions at a concentration of 1.5 x 107 cells ml'. The total number of 
Results
Production of chemokine in transfectants Twelve independent G418-resistant colonies from each transfection of chemokine expression plasmid were isolated and expanded. One clone showing the highest level of mRNA expression for chemokine was selected for further study by the RNA blotting method, as shown in Figure 1 . The CHO cells transfected with vector alone (CHO/neo: control) did not express any cross-hybridising endogenous chemokine genes. Furthermore, the production of chemokine was confirmed by assays of chemotactic activity, ELISA and/or RIA (Table I) . Individual transfectants secreted substantial levels of chemokine activity, while control transfectant produced no chemotactic factor. (Colombo and Forni, 1994) . Transfection with virtually almost all cytokine genes results in inhibition of tumour CHO/neo plus CHO/mu-MIP-lcx Ours is the first report demonstrating the inhibition of tumour growth in nude mice by secretion of IL-8 or MIP-1x, and this was accompanied by neutrophilic infiltration. Both CHO purified IL-8 and MIP-I have been reported to act on several types of immune cells (Oppenheim et al., 1991) but did not show tumour cell killing activity in vitro. On the basis of their in vitro properties Oppenheim et al., 1991) (Lloyd and Oppenheim, 1992) .
Interestingly, mu-MIP-2, which has also been reported to be a chemokine for neutrophils in vitro (Anisowicz et al., 1987) , showed only a very low level of neutrophilic infiltration, similar to that of the controls, and had no anti-tumour activity. This was perhaps due to insufficient attraction of neutrophils by the MIP-2-transfected cells. Although two research groups have independently demonstrated MCP-1 (MCAF, JE) secretion by transfected tumour induced monocyte-mediated tumoricidal activity in syngeneic (Bottazi et al., 1992) and nude mice (Rollins and Sunday, 1991), we did not observe the suppression of tumour growth and monocytic infiltration at the injection site of MCP-1-producing tumour cells. This discrepancy might derive from differences in the level of MCP-1 production by tumour cells. We may not have achieved optimal concentration of this chemokine for chemotactic effects on monocytes in vivo. It is also possible that CHO cells spontaneously produce certain cross species-reactive cytokines which may have influenced the chemotactic activities of chemokine produced by the transfectants.
We have observed that mu-MIP-lcx had much more potent tumoricidal activity than hu-MIP-lI in nude mice, perhaps because of species differences. Histological examination demonstrated that mu-MIP-lI resulted in greater accumulation in mu-neutrophils than hu-MIP-lcm. Nevertheless, hu-MIP-lac is quite cross species-reactive, as previously reported (Dunlop et al., 1992) . The mixed tumour transplantation assay demonstrated that the effects of hu-IL-8 and mu-MIP-hi were transmitted from producer to non-producer cells.
It was recently reported that gene transfer of IP-10, which is a member of the C-X-C chemokines superfamily, elicited a more potent host-mediated anti-tumour effect in syngeneic, immunocompetent mice than in immunoincompetent nude mice (Luster and Leder, 1993) . The anti-tumour response of IP-10 is T lymphocyte dependent, not limited to secreting cells, and appears to be mediated by the recruitment of cell infiltrate composed of T lymphocytes in vivo. Since IL-8 is, also, a potent chemoattractant for T lymphocytes , an enhanced anti-tumour effect might be expected in syngeneic, immunocompetent mice, but this remains to be shown. On the other hand, MIP-la is unlikely to show more potent anti-tumour effects in syngeneic than in nude mice, because the injection site (s.c.) of Lewis lung carcinoma cells transfected with mu-MIP to syngeneic mice contained very few infiltrating T lymphocytes (data not shown).
Although IL-8 was originally identified as a neutrophil chemoattractant, subsequent work has revealed its multifunctionality, as is the case with most cytokines. IL-8 can induce the migration of some tumour cells (Wang et al., 1990) and stimulate the growth of melanoma cells (Schadendorf et al., 1993) . IL-8 has also been shown to be an angiogenic factor released by activated macrophage Strieter et al., 1992) . Since cell migration, proliferation and angiogenesis are all essential components of the metastatic process (Fidler et al., 1990) , IL-8 expression by tumour cells may influence their metastatic capabilities. In fact, a recent paper has clearly demonstrated that the expression level of IL-8 correlated with the metastatic potential of human melanoma cells implanted into nude mice (Singh et al., 1994) . However, we have not observed metastatic behaviour in CHO cells transfected with IL-8 in nude mice (data not shown). These contradictory observations may be explained by differences in the metastatic potential of different tumour cell types. Factors in addition to IL-8 production might be required for metastasis of CHO tumour cells.
The fact that MIP-bI, a C-C chemokine, results in the accumulation of neutrophils, but not of monocytes, in our in vivo study was quite unexpected, because C-C chemokines have been thought to be predominantly chemotactic for monocytes (Oppenheim et al., 1991) .
The local injection of immunomodulating agents such as LPS and PSK (protein-bound polysaccharide) (Nakazato et al., 1994) , which are potent inducers of chemokines, at the tumour site (Matsushima et al., 1988; Hirose et al., 1990) , could lead to tumour cell killing based on local chemokine secretion.
Chemokines may be useful clinically in combination with anti-cancer agents and/or other types of cytokines such as IL-2, IFNs, and CSFs, since they seem to have different anti-tumour mechanisms and to be well tolerated at high doses. This leads us to hypothesise that engineering tumourinfiltrating lymphocytes (TILs) to express a chemokine might provide synergistic local tumour cell killing.
